BridgeBio Pharma Gross Margin 2018-2024 | BBIO

Current and historical gross margin for BridgeBio Pharma (BBIO) over the last 10 years. The current gross profit margin for BridgeBio Pharma as of September 30, 2024 is %.
BridgeBio Pharma Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-09-30 $0.22B $0.22B 99.08%
2024-06-30 $0.22B $0.22B 99.09%
2024-03-31 $0.22B $0.22B 98.63%
2023-12-31 $0.01B $0.01B 60.00%
2023-09-30 $0.01B $0.01B 60.00%
2023-06-30 $0.01B $0.00B 50.00%
2023-03-31 $0.08B $0.08B 96.15%
2022-12-31 $0.08B $0.07B 94.87%
2022-09-30 $0.09B $0.08B 94.38%
2022-06-30 $0.09B $0.09B 93.41%
2022-03-31 $0.07B $0.07B 92.96%
2021-12-31 $0.07B $0.07B 95.65%
2021-09-30 $0.06B $0.06B 98.21%
2021-06-30 $0.06B $0.06B 100.00%
2020-09-30 $0.02B $0.02B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00